Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 46 recruiting now early-phase tilt #130 of 28,707 conditions

Mantle Cell Lymphoma: early-phase trial registry

46 of 103 indexed Mantle Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #130 of 28,707 conditions by registered trial count.

103 US clinical trials · 46 currently recruiting · #130 of 28,707 conditions by registered trial count

Mantle Cell Lymphoma: 103 US clinical trials tracked, 46 recruiting.

Mantle Cell Lymphoma is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 46 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.

Enrollment posture brief

Registry condition mantle-cell-lymphoma

OPEN 46 | RECR 45% | LATE 7 | EARLY 86 | RANK #130 | SPON 12

Nearest open-share peer: Food Insecurity (45% recruiting · 38 trials)

Amyotrophic Lateral Sclerosi45.6%Mantle Cell Lymphoma (this)45%Chronic Kidney Disease31.1%Attention Deficit Hyperactiv28.2%Metabolic Syndrome26.9%
Open-enrollment share among volume-matched conditions near Mantle Cell Lymphoma

Mantle Cell Lymphoma lists 46 open slots (45% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mantle Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Mantle Cell Lymphoma is recruiting above its size-band peers.

    46 of 103 indexed trials (44.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Mantle Cell Lymphoma trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 12 of 103 trials (11.7%). 71 distinct sponsors appear on at least one study for this condition label.

  3. Most Mantle Cell Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 43 among the 103 trials that report a genuine target (sentinel values excluded). 73 of those (70.9%) plan for fewer than 100 participants.

  4. Mantle Cell Lymphoma research is mostly interventional.

    96 interventional and 7 observational studies make up this index (93.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 146Phase 240Phase 37

Phase Distribution

PhaseTrial count
Phase 1 46
Phase 2 40
Phase 3 7

Named interventions

Most-linked intervention names on Mantle Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Rituximab Drug
15 trials
Cyclophosphamide Drug
12 trials
Acalabrutinib Drug
11 trials
Bendamustine Drug
10 trials
Ibrutinib Drug
10 trials
Cytarabine Drug
8 trials
Rituximab Biological
7 trials
Bone Marrow Biopsy Procedure
7 trials

US sites by state

Facility locations filed on Mantle Cell Lymphoma trials. A trial with sites in several states counts in each.

California 38 trials
Texas 25 trials
New York 20 trials
Massachusetts 18 trials
Colorado 14 trials
North Carolina 13 trials
Maryland 13 trials
Illinois 13 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Mantle Cell Lymphoma page

103 registered trials, 46 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mantle Cell Lymphoma condition card totals 103 registered trials; most-linked intervention Rituximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.